Litchfield Hills Research Estimates Mainz Biomed Q2 Earnings

Mainz Biomed NV (NASDAQ:QUCY) – Litchfield Hills Research issued their Q2 2026 earnings per share estimates for shares of Mainz Biomed in a research note issued to investors on Monday, August 10th. Litchfield Hills Research analyst T. O’neill expects that the company will earn ($0.63) per share for the quarter. Litchfield Hills Research has a “Strong-Buy” rating on the stock. Litchfield Hills Research also issued estimates for Mainz Biomed’s Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($1.12) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.12) EPS, FY2027 earnings at ($0.55) EPS, Q1 2028 earnings at ($0.10) EPS, Q2 2028 earnings at ($0.04) EPS and FY2028 earnings at ($0.07) EPS.

Other research analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mainz Biomed in a research note on Friday. Wall Street Zen upgraded shares of Mainz Biomed to a “hold” rating in a research report on Saturday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold”.

Mainz Biomed Stock Performance

Shares of QUCY opened at $1.37 on Wednesday. Mainz Biomed has a 12 month low of $0.30 and a 12 month high of $4.93. The firm has a 50 day simple moving average of $1.51. The firm has a market capitalization of $20.08 million, a price-to-earnings ratio of -0.03 and a beta of 2.31.

Key Stories Impacting Mainz Biomed

Here are the key news stories impacting Mainz Biomed this week:

• Positive Sentiment: Litchfield Hills Research upgraded Mainz Biomed to “Strong Buy”, providing a positive sentiment catalyst for the shares. Zacks report on Mainz Biomed analyst upgrade
• Positive Sentiment: The firm projects that Mainz Biomed’s losses will narrow significantly over time, from an estimated $1.12 loss per share in fiscal 2026 to $0.55 in fiscal 2027 and $0.07 in fiscal 2028. Quarterly estimates also improve from a $0.63 loss in the second quarter of 2026 to a $0.04 loss in the second quarter of 2028, suggesting expectations for long-term operating progress. MarketBeat Mainz Biomed analyst estimates
• Neutral Sentiment: Reported short interest was zero shares as of August 11, with a short-interest ratio of zero days. This indicates no meaningful disclosed short-selling pressure, although the data does not provide a direct catalyst for the stock.
• Negative Sentiment: The analyst forecasts still show substantial losses through 2028, meaning Mainz Biomed remains dependent on execution, financing, and future commercialization progress. The stock’s market capitalization is approximately $20 million, its beta is 2.31, and it was trading below its 50-day moving average of $1.51, underscoring elevated volatility and downside risk.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.